(Reuters) - Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Shares of Novavax NVAX lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on its experimental COVID-19-Influenza Combination (“CIC”) and stand ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...